An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome
Latest Information Update: 03 May 2012
At a glance
- Drugs Fenobam (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions; Pharmacodynamics
- 03 May 2012 New trial record